Effect of exercise interventions on hand grip and TUG in older adults: A network meta-analysis of randomized controlled trials.

Arch Gerontol GeriatrMay 28, 2026 (epub)
Clinical ResearchGeriatricsPhysical Medicine & Rehabilitation

María López-González, Celia Álvarez-Bueno, Miguel Contreras-Molina et al.

✦ AI-curated · Sources linked

In 30 seconds

This network meta-analysis evaluated the effects of various exercise interventions on hand grip strength and functional mobility in older adults. Among 47 randomized controlled trials, multicomponent exercise combined with nutritional support showed the largest improvement in hand grip strength (effect size 6.39) and the greatest reduction in Timed Up and Go (TUG) time (effect size -1.88) compared to control groups.

Key findings

  • Multicomponent exercise plus nutritional support improved hand grip strength with an effect size of 6.39.
  • Resistance training plus nutritional support also improved hand grip strength with an effect size of 3.63.
  • Multicomponent exercise plus interventions reduced TUG time by an effect size of -1.88 compared to control.
  • Multicomponent exercise showed superiority over conventional combined exercise with an effect size of -1.68 for TUG.

Why it matters

The findings highlight the importance of integrating exercise and nutritional strategies to enhance muscle strength and mobility in older adults, which is crucial for maintaining independence and reducing frailty.

Source

PubMed · PMID 42241794

Published in Arch Gerontol Geriatr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.